Nosografia dos Transtornos Afetivos: um recorte histórico de Kraepelin ao DSM-5 / Nosography of Affective Disorders: A historical review from Kraepelin to DSM-5 / Nosographie des troubles affectifs: un aperçu historique de Kraepelin au DSM-5 / Nosografia de los trastornos afectivos: un corte histórico de Kraepelin al DSM-5

A nosografia dos transtornos do humor e do afeto relaciona-se diretamente com as formas de apreensão dos quadros clínicos em cada contexto histórico. É indagado se o resgate histórico contribuiria para melhor compreensão e utilização da atual nosologia dos transtornos de humor. Objetiva-se realizar uma revisão histórica e crítica acerca de suas transformações conceituais e nosológicas com enfoque ao campo médico-psiquiátrico. O recorte pretendido se inicia com a proposição da "Insanidade Maníaco-Depressiva" por Emil Kraepelin em 1899, que é confrontada com as propostas pós-kraepelianas, em especial as de Karl Leonhard. Analisa-se a influência dessas na criação dos sistemas diagnósticos operacionalizados, DSM e CID. O "Transtorno Bipolar" foi um constructo introduzido pelo DSM-III e se mantém em uso até os dias atuais. Aborda-se também propostas posteriores, como a do "Espectro Bipolar".

Nosography of mood and affective disorders is directly related to how clinical pictures are understood in each historical context. Inquiring on whether a historical recollection would contribute to a better understanding and use of the current nosology of mood disorders, the study carries out a historical and critical review of its conceptual and nosological transformations on the medical-psychiatric field. Starting from Emil Kraepelin's "Manic-Depressive Insanity," proposed in 1899, the text confronts this concept with post-Kraepelian proposals, especially those of Karl Leonhard. It then analyzes their influence in the creation of two operationalized diagnostic systems — DSM and ICD. "Bipolar Disorder," a construct introduced by the DSM-III, remains in use today. Later proposals are also addressed, such as the "Bipolar Spectrum".

La nosographie des troubles de l'humeur et des troubles affectifs est directement liée à la manière dont les tableaux cliniques sont compris dans chaque contexte historique. En se demandant si un rappel historique contribuerait à une meilleure compréhension et utilisation de la nosologie actuelle des troubles de l'humeur, l'étude procède a un examen historique et critique de ses transformations conceptuelles et nosologiques dans le domaine médico-psychiatrique. Partant de la "Folie maniaco-dépressive" d'Emil Kraepelin, proposée en 1899, l'article confronte ce concept aux propositions post-Kraepeliennes, notamment celles de Karl Leonhard. On analyse ensuite leurs influence dans la création de systèmes de diagnostic opérationnalisés — le DSM et la CIM. Le "trouble bipolaire", une construction introduite par le DSM-III, est toujours utilisé aujourd'hui. D'autres propositions sont égalemment abordées, comme le "spectre bipolaire".

La nosografía de los trastornos afectivos está directamente relacionada con las formas en que se aprehenden las condiciones clínicas en cada contexto histórico. Se pregunta si la revisión histórica contribuiría a una mejor comprensión y uso de la nosología actual de los trastornos del humor. El objetivo de este artículo es realizar una revisión histórica y crítica de sus transformaciones conceptuales y nosológicas con un enfoque en el campo médico-psiquiátrico. El recorte comienza con la propuesta en el texto "Locura maníaco-depresiva", de Emil Kraepelin, en 1899, que se enfrenta a propuestas postkraepelianas, especialmente las de Karl Leonhard. Se analiza la influencia de estas propuestas en la creación de sistemas diagnósticos operacionalizados, el Manual Diagnóstico y Estadístico de los Trastornos Mentales (DSM) y la Clasificación Internacional de Enfermedades (CID). El "trastorno bipolar" es una construcción introducida por el DSM-3 y sigue en uso hoy. También se abordan propuestas posteriores, como la del "espectro bipolar".

[Comorbidity of affective disorders and alcohol use disorder]. / Troubles affectifs et comorbidités éthyliques.

The comorbidity of affective disorders with alcohol use disorder remains insufficiently taken into account. In spite of the well-known frequency of the addict comorbidity in most psychiatric disorders, the level of association between affective disorders and alcohol is still underestimated and poorly understood. The label of "double diagnosis" relates to a simple addition of two independent pathologies. It is suggested to consider a "dual psychopathology" combining the effects of one disorder on the other. Interactions between the two disorders commit a complex state calling a new clinical reading, an adapted therapeutic strategy through a necessary integration of care. Association of alcohol use disorder and affective disorder, particularly in bipolar disorders, is correlated with severity, unstable course, treatment resistance and a greater risk of suicide. Alcohol aggravates depression and hampers therapeutics. Alcohol and mania remain a dreaded danger. The mechanism of the comorbid association does not only refer to a behavioral strategy of compensation but seems strongly based on a shared and crossed vulnerability, related to the genetics of the 5HT carrier and gene Clock. Therapeutic limitations do suggest the implementation of an "integrated" device which supposes a new organization of care and facilitation of collaborations between Addiction and Psychiatry.

[Affective disorders: endocrine and metabolic comorbidities]. / Troubles affectifs et comorbidités endocrino-métaboliques.

Links between affective and endocrine-metabolic disorders are numerous and complex. In this review, we explore most frequent endocrine-metabolic comorbidities. On the one hand, these comorbidities imply numerous iatrogenic effects from antipsychotics (metabolic side-effects) or from lithium (endocrine side-effects). On the other hand, these comorbidities are also associated with affective disorders independently from medication. We will successively examine metabolic syndrome, glycemic disturbances, obesity and thyroid disorders among patients with affective disorders. Endocrinemetabolic comorbidities can be individually encountered, but can also be associated. Therefore, they substantially impact morbidity and mortality by increasing cardiovascular risk factors. Two distinct approaches give an account of processes involved in these comorbidities: common environmental factors (iatrogenic effects, lifestyle), and/or shared physiological vulnerabilities. In conclusion, we provide a synthesis of important results and recommendations related to endocrine-metabolic comorbidities in affective disorders : heavy influence on morbidity and mortality, undertreatment of somatic diseases, importance of endocrine and metabolic side effects from main mood stabilizers, impact from sex and age on the prevalence of comorbidities, influence from previous depressive episodes in bipolar disorders, and relevance of systematic screening for subclinical (biological) disturbances.

[Affective disorders and neurological comorbidities]. / Troubles affectifs et comorbidités neurologiques.

Mood disorders occupy a vast area in the field of psychiatry. Advances in the study of the brain, but also epidemiology and genetics allow us to make more solid connections between these disorders and neurological disorders, resuming a process of reconciliation between both specialties. The purpose of this short review is to draw the attention of the psychiatrist to these links, especially with a brief presentation of the psychiatric manifestations of a number of neurodegenerative diseases and more particularly frontotemporal dementia.

[Dissociative disorders and affective disorders]. / Troubles dissociatifs et troubles affectifs.

The phenomenology of dissociative disorders may be complex and sometimes confusing. We describe here two cases who were initially misdiagnosed. The first case concerned a 61 year-old woman, who was initially diagnosed as an isolated dissociative fugue and was actually suffering from severe major depressive episode. The second case concerned a 55 year-old man, who was suffering from type I bipolar disorder and polyvascular disease, and was initially diagnosed as dissociative fugue in a mooddestabilization context, while it was finally a stroke. Yet dissociative disorders as affective disorder comorbidity are relatively unknown. We made a review on this topic. Dissociative disorders are often studied through psycho-trauma issues. Litterature is rare on affective illness comorbid with dissociative disorders, but highlight the link between bipolar and dissociative disorders. The later comorbidity often refers to an early onset subtype with also comorbid panic and depersonalization-derealization disorder. Besides, unipolar patients suffering from dissociative symptoms have more often cyclothymic affective temperament. Despite the limits of such studies dissociative symptoms-BD association seems to correspond to a clinical reality and further works on this topic may be warranted.

[Co-occuring mood and substance use disorders]. / Troubles affectifs et comorbidités addictives en dehors de l'alcool.

Mood and substance use disorders commonly co-occur, yet there is little evidence-based research to guide the pharmacologic management of these comorbid disorders. The authors review the existing empirical findings including current clinical pharmacotherapy practices for treating co-occurring mood and substance use disorders and call into question current clinical practices. The specific mood disorders reviewed are bipolar and major depressive disorders (either one co-occurring with a substance use disorder). The authors also highlight knowledge gaps that may serve as a basis for future research. Findings from the relatively small amount of available data indicate that pharmacotherapy for managing mood symptoms might be effective in patients with substance dependence, although results have not been consistent across all studies. In most studies, medications for managing mood symptoms did not appear to have an impact on the substance use disorder. Research has only begun to address optimal pharmacologic management of co-occurring disorders. In addition, current clinical treatment for drug dependence often exclude new pharmacotherapies approved by the French Haute Autorité de Santé for treating certain types of addiction. With new data becoming available, it appears that we need to revisit current practice in the pharmacological management of co-occurring mood and substance use disorders.